Zinzino (ZZ-B.ST) Stock Analysis & AI Equity Report

Household & Personal Products SEK Explore free reports

Zinzino (ZZ-B.ST) overview

Zinzino (ZZ-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Zinzino reported revenue of SEK 3,172m and operating profit of SEK 245m; the year-end share price was 159.20 SEK and market capitalisation was SEK 5,678m. Zinzino is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Zinzino's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 706mFY 2025
Share price159.20 SEKFY 2025 year end
RevenueSEK 3,172mFY 2025
Operating profitSEK 245mFY 2025
Net earningsSEK 325mFY 2025
Market capitalisationSEK 5,678mFY 2025 year end

Figures updated on 2026-05-21. Data will be refreshed during report generation.

About Zinzino

Zinzino AB develops, markets and sells test-based nutritional supplements, including omega-3 products, along with skincare and other wellness products through a direct sales model with independent partners. The company also uses blood-based health tests and digital tools to support personalized supplement routines, and it has expanded through acquisitions in related health and nutrition businesses.

Generate the Zinzino report

Zinzino is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Zinzino and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.